RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: all available years, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Your saved research and appointment questionsView recorded trial and retraction changes
15q13.3 Microdeletion Syndrome: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Prenatal diagnosis of 15q13.3 deletion and duplication syndrome: what do we tell the prospective parents?
Luo Xiaojin et al., Archives of gynecology and obstetrics (1 December 2025)
https://pubmed.ncbi.nlm.nih.gov/41123664/
- 2.
15q13.2q13.3 microdeletion syndrome with congenital stationary night blindness due to compound deletion and a missense point mutation in TRPM1 gene
Justyna Pietrasik et al., Pediatria Polska (19 November 2025)
https://doi.org/10.5114/polp.2025.156306
- 3.
Augmented hippocampal up-regulation of immune modulators following a peripheral immune challenge in a hemizygous mouse model of the 15q13.3 microdeletion.
Rees Katherine A et al., Cytokine (1 July 2025)
https://pubmed.ncbi.nlm.nih.gov/40300236/
- 4.
Case reports of two siblings with autism spectrum disorder and 15q13.3 deletions.
Furukawa Sawako et al., Neuropsychopharmacology reports (1 September 2023)
https://pubmed.ncbi.nlm.nih.gov/37264739/
- 5.
Impaired OTUD7A-dependent Ankyrin regulation mediates neuronal dysfunction in mouse and human models of the 15q13.3 microdeletion syndrome.
Unda Brianna K et al., Molecular psychiatry (1 April 2023)
https://pubmed.ncbi.nlm.nih.gov/36604605/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
15q13.3 Microdeletion Syndrome
15q13.3 microdeletion syndrome is caused by a missing piece of chromosome 15. It is linked with developmental delay, learning difficulties, seizures and behavioural or mental health conditions, though some people who carry the deletion have few or no signs. Features vary widely between family members. Care is tailored to the individual and may include epilepsy treatment, therapies and school support.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
15q13.3 Microdeletion Syndrome is very rare and little research has been published, so this page includes research from every year, including case reports about individual patients. Case reports are marked, and describe one person's experience rather than tested results.
Most Recent Research
OBJECTIVE: This retrospective study analyzed ultrasound findings, single nucleotide polymorphism microarray (SNP array) results, pregnancy outcomes, and postnatal follow-up data in fetuses with 15q13.3 deletions or duplications. METHODS: Six fetuses were diagnosed with 15q13.3 deletions and nine with 15q13.3 duplications via SNP array at the prenatal diagnosis center of a single tertiary medical center from August 2017 to December 2024. Maternal demographics, ultrasound findings, SNP array results, pregnancy outcomes, and follow-up information were comprehensively reviewed and analyzed. RESULTS: The deletions sizes in the six deletions ranged from 744 Kb to 1.87 Mb, primarily involving genes such as MTMR15, MTMR10, TRPM1, KLF13, OTUD7A, and CHRNA7. The overlapping region was located between 31.9 Mb and 32.5 Mb. In the nine duplication cases, the fragment sizes ranged from 419 Kb to 2.13 Mb, with overlapping region located between 31.9 Mb and 32.4 Mb. Among the six cases of fetal deletions, three (50.0%, 3/6) exhibited ultrasound abnormalities. The observed ultrasound phenotypes primarily consisted of cardiovascular malformations, lateral ventriculomegaly, intrauterine growth retardation, cleft lip and palate, abnormal finger development, and polyhydramnios. In the nine cases with fetal duplications, four (44.4%, 4/9) showed ultrasound abnormalities, predominantly featuring cardiovascular malformations, corpus callosum hypoplasia, enlarged gallbladder, lateral ventriculomegaly, and increased nuchal translucency. Among the six deletions cases, parental origin testing was conducted for five cases, two were identified as maternally inherited and three were de novo. In the nine duplications cases, eight underwent parental origin testing, with five being inherited (three paternal and two maternal) and two were de novo. Follow-up assessments revealed that the Case 7 showed speech and motor developmental delays. Case 8 experienced seizure at four years of age. At 18 months, Case 13 was diagnosed with bilateral strabismus. CONCLUSION: This study conducted a preliminary assessment of the genotype and phenotype of fetuses with 15q13.3 deletions/duplications, expanding the phenotypic spectrum of this syndrome. The study suggests that prenatal 15q13.3 deletions and duplications may be associated with cardiac malformations and lateral ventriculomegaly, but lack phenotype specificity. Moreover, it is essential to closely monitor the neuropsychiatric development postnatally in fetuses with 15q13.3 deletions and duplications that exhibit normal phenotypes during the prenatal period.
Common Questions
What is 15q13.3 Microdeletion Syndrome?
15q13.3 microdeletion syndrome is caused by a missing piece of chromosome 15. It is linked with developmental delay, learning difficulties, seizures and behavioural or mental health conditions, though some people who carry the deletion have few or no signs. Features vary widely between family members. Care is tailored to the individual and may include epilepsy treatment, therapies and school support.
How many clinical trials are available for 15q13.3 Microdeletion Syndrome?
No clinical trials are currently indexed for 15q13.3 Microdeletion Syndrome. This may change as new trials are registered. Check back regularly or visit ClinicalTrials.gov directly.
Where does the research data for 15q13.3 Microdeletion Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for 15q13.3 Microdeletion Syndrome.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.